Glenmark Pharmaceuticals Inc., USA, is set to launch its Potassium Phosphates Injection USP in March 2026, offering single-dose vials and pharmacy bulk package vials. The product is bioequivalent to Fresenius Kabi‘s reference drug.
The Potassium Phosphates Injection USP will be available in 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL single-dose vials, and 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package vials. According to IQVIA sales data, the market for these injections achieved annual sales of approximately $50.7 million as of January 2026.
Marc Kikuchi, President & Business Head, North America, commented on the launch, expressing Glenmark’s commitment to expanding its product portfolio within the institutional channel and providing affordable alternatives for patients.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).